Brekiya Generic: When Will Generic Dihydroergotamine Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Brekiya Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? August 2039 About 13 years away Why then?
- Has the FDA approved a generic? Unknown No FDA Orange Book record under this name
- When does the brand’s protection end? Unknown Not in the FDA record we could read
- Can you buy a generic today? Yes 16 companies list one in some form
A generic matching Brekiya is expected to be available in August 2039, about 13 years away. A generic dihydroergotamine mesylate is already listed for sale in some form by 16 companies, so ask your pharmacy whether one matches Brekiya.
Why August 2039?
A patent that protects the brand runs out. After that, approved generics can be sold. We rate it probable: more likely than not, but it can still move.
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Brekiya, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Brekiya by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- Medicare Part D spent $279.6K in 2025, for 21 people CMS Part D Spending by Drug
- Medicaid prescriptions 28 in the last four reported quarters, $119.3K CMS Medicaid drug utilization, to Q1 2026
Brekiya’s Road to a Generic
The first generic of Brekiya is expected in August 2039.
Why that month: a patent that protects the brand runs out. After that, approved generics can be sold.
The bar shows Brekiya on the market on its own until the month we expect the first generic (the green band), a month and never a day. Its approval date and patents are not in the FDA Orange Book under this name, so the bar fades in from the left. The expected month comes from court records and company announcements.
Who Is Lined Up to Make Generic Dihydroergotamine Mesylate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Brekiya yet.
Approved by the FDA
We could not find Brekiya’s own record in the FDA Orange Book under this name, so the approved generic makers are not shown.
For Sale in Pharmacies
Yes. A generic dihydroergotamine mesylate in some form is listed for sale by 16 companies. Ask your pharmacy whether it can fill your prescription with it.
Advagen Pharma Ltd, Amneal Pharmaceuticals NY LLC, Apollo Pharmaceuticals Inc., Baxter Healthcare Corporation, Gland Pharma Limited, Hikma Farmaceutica and 10 more
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Brekiya Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Brekiya, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Brekiya
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Brekiya, before manufacturer rebates.
- $958.1K
- January to March 2026, the latest CMS has posted
For 72 people, about $7,544 per prescription fill - $279.6K
- 2025, the whole year
For 21 people, about $6,503 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $958,062 | 72 | $7,543.79 |
| 2025 | $279,628 | 21 | $6,502.97 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Brekiya only, so no generic is counted in it. What CMS says it is used for: Dihydroergotamine is used to treat migraine headaches and cluster headaches. It is not recommended for migraines that affect only one side of the brain (hemiplegic migraine) or the base of the brain/neck area (basilar migraine), or to prevent migraines from occurring.
Medicaid Prescriptions by Quarter
28 prescriptions in the four quarters to Q1 2026, $119.3K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 28 | $119,338 |
| Q4 2025 | 0 | $0 |
Source: CMS Medicaid State Drug Utilization Data, over Brekiya’s own package codes.
Brekiya NDC Codes and Packages
Each Brekiya package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 64896-0509-02 | DIHYDROERGOTAMINE MESYLATE 1 mg/mL injection | carton of 4 pouches of 1 syringe of 1 mL | Amneal Pharmaceuticals LLC |
Source: the FDA NDC Directory, current listings only. Some codes belong to companies that repackage Brekiya: it is the same medicine in a different package.
What a Generic Brekiya Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Brekiya
Is there a generic for Brekiya right now?
Yes. The FDA NDC Directory lists a generic dihydroergotamine mesylate in some form from 16 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Brekiya go generic?
August 2039 is the expected month, and that is probable but not certain. A patent that protects the brand runs out. After that, approved generics can be sold.
Will generic dihydroergotamine mesylate be the same as Brekiya?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Changes to This Projection
- First generic expected August 2039 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- NulibryFosdenopterin HydrobromideApril 2029
- Alkindi SprinkleHydrocortisoneJanuary 2033
- ScenesseAfamelanotideJanuary 2033
- InveltysLoteprednol EtabonateMay 2033
- VevyeCyclosporineSeptember 2037
- Dilaudid-HPHydromorphone HydrochlorideTBD no date yet
About Brekiya
- Generic name dihydroergotamine mesylate
- How it is taken Injection
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with B
- Have a question? A pharmacist answers, free. Ask about Brekiya
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.